Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
نویسندگان
چکیده
Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors' critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
منابع مشابه
Overcoming docetaxel resistance in prostate cancer: a perspective review
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate cancer. Toxicity is typical of other cytotoxic agents, with myelosuppression being the dose-limiting toxicity and neurotoxicity also a notable side effect for ...
متن کاملA combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
Castrate-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Several tyrosine kinases have been implicated in the development and growth of CRPC, as such targeting these kinases may offer an alternative therapeutic strategy. We established the combination of two tyrosine kinase inhibitors (TKIs), sorafenib and nilotinib, as the most cytotoxic. In addtion, ...
متن کاملCastrate-resistant Prostate Cancer— Recent Advances in Therapy and Future Perspectives
For many years, few therapeutic options were available for the treatment of advanced prostate cancer. Recent advances in our understanding of the molecular biology of prostate cancer, particularly in the transition to castrate resistant disease, have led to the development of more potent and selective endocrine therapies. In addition, elucidation of the many factors in the bone microenvironment...
متن کاملNew Therapeutics to Treat Castrate-Resistant Prostate Cancer
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage pros...
متن کاملCrosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer
Castrate-resistant prostate cancer (CRPC) is the fatal form of prostate cancer. Although reactivation of androgen receptor (AR) occurs following androgen deprivation, the precise mechanism involved is unclear. Here we show that the receptor tyrosine kinase, RON alters mechanical properties of cells to influence epithelial to mesenchymal transition and functions as a transcription factor to diff...
متن کامل